Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden. Its product pipeline consists of Lipisense project, which is in phase II for the treatment of severe hypertriglyceridemia disease; Dyslipidemia project, which is in preclinical trial to treat cardiovascular disease and severe hypertriglyceridemia; and CAP project, which is in preclinical trial to treat and prevent lung injury associated with community-acquired pneumonia. The company has a license agreement with Leaderna for the development of Lipisense. The company was incorporated in 2010 and is based in Umeå, Sweden.
Show more...
FAQ
Lipigon Pharmaceuticals AB 今天的股價是多少?▼
LPGO-BTA.ST 目前價格為 SEK0.09 SEK,過去 24 小時上漲了 +0%。在圖表上更密切關注 Lipigon Pharmaceuticals AB 股價表現。
Lipigon Pharmaceuticals AB 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 Stockholm Exchange 交易所,Lipigon Pharmaceuticals AB 的股票以代號 LPGO-BTA.ST 進行交易。
Lipigon Pharmaceuticals AB 的市值是多少?▼
今天 Lipigon Pharmaceuticals AB 的市值為 54.17M
Lipigon Pharmaceuticals AB 去年的營收是多少?▼
Lipigon Pharmaceuticals AB 去年的營收為 10.29MSEK。
Lipigon Pharmaceuticals AB 去年的淨利是多少?▼
LPGO-BTA.ST 去年的淨收益為 -25.26MSEK。
Lipigon Pharmaceuticals AB 有多少名員工?▼
截至 September 10, 2026,公司共有 5 名員工。
Lipigon Pharmaceuticals AB 位於哪個產業?▼
Lipigon Pharmaceuticals AB從事於Health & Wellness產業。
Lipigon Pharmaceuticals AB 何時完成拆股?▼
Lipigon Pharmaceuticals AB 最近沒有進行任何拆股。
Lipigon Pharmaceuticals AB 的總部在哪裡?▼
Lipigon Pharmaceuticals AB 的總部位於 瑞典 的 Umeå。